🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

ozios_close
Mobile app

Download our mobile application and trade without restrictions. You can have all your investments in your pocket and under control wherever you go.

Moderna stocks expand to record highs

During last year, Moderna stocks surpassed wider market and experienced record growth of 509% (to the date of 26th August 2021). The value exceeded total returns of the S&P 500 index reaching 28% (to the date of 26th August 2021). The pharmaceutical company recorded success last performed by Tesla Inc.

During last year, Moderna stocks surpassed wider market and experienced record growth of 509%[1] (to the date of 26th August 2021). The value exceeded total returns of the S&P 500 index reaching 28%[2] (to the date of 26th August 2021). The pharmaceutical company recorded success last performed by Tesla Inc.

The S&P 500 index represents one of the most important stock indices globally. It contains 500 largest publicly traded companies in the U.S. weighted by market share[3].

Good news keep on coming for Moderna stocks. Firstly, the vaccine shows high efficacy up to six months after second dose, while efficacy of vaccine manufactured by Pfizer Inc and BioNTech wanes by an average of six percentage points every two months. About six months after a second dose, the efficacy slipped to 84%, while Moderna maintains its standard.

“Our COVID-19 vaccine is showing durable efficacy of 93% through six months, yet the Delta variant is a significant new threat so we must remain vigilant,” said Stéphane Bancel, Chief Executive Officer of Moderna. The company has reported that a third dose may be needed to prolong the body's immune response and provide protecting even against the Delta variant.

The company has been testing different types of COVID-19 vaccine in order to provide effective protection against specific coronavirus variants. AFP reported that these vaccines have demonstrated high antibody responses, yet no further information is clear for now.

Thanks to the vaccine, Moderna reported first-quarter net income in 2021[4]. While the pharma company reached net income of $1.22 billion in first quarter, it reported a loss of $124 million in the same period a year earlier. The drop could have been caused by high research and development expenses, what later positively impacted economic results.

Similarly, Moderna reported high revenues of $1.9 billion compared to $8 million in the same period last year, while vaccine revenues alone reached $ 1.7 billion. Nevertheless, the results fell short of analysts' estimates, who had predicted revenues worth $2 billion.

The company reported good economic results and higher than expected profit even in second quarter.

Based on the Ozios analysis, we may expect that Moderna (as well as other pharmaceutical companies developing COVID-19 vaccines) could report solid profits even in the near future. The company's sales could grow thanks to the third shot of COVID-19 vaccines for people with compromised immune systems[5]. The dose has been approved by the US Food and Drug Administration (FDA) few days ago and Germany, Chile and Israel have approved its application.

On the other hand, competition in the field is growing constantly, and some new companies may enter the market in the long run. A slight correction of sales of pharmaceutical companies providing COVID-19 vaccine may come along with them.

 

[1] https://www.investing.com/equities/moderna

[2] https://www.investing.com/indices/us-spx-500

[3] https://cs.wikipedia.org/wiki/S%26P_500

[4] https://apnews.com/article/earnings-business-2727f3c1ad030ee834d8ed9292b0256e

[5] https://www.reuters.com/world/middle-east/us-fda-authorizes-covid-19-vaccine-boosters-immunocompromised-2021-08-13/

Moderna stocks expand to record highs

During last year, Moderna stocks surpassed wider market and experienced record growth of 509% (to the date of 26th August 2021). The value exceeded total returns of the S&P 500 index reaching 28% (to the date of 26th August 2021). The pharmaceutical company recorded success last performed by Tesla Inc.

Moderna stocks expand to record highs

During last year, Moderna stocks surpassed wider market and experienced record growth of 509% (to the date of 26th August 2021). The value exceeded total returns of the S&P 500 index reaching 28% (to the date of 26th August 2021). The pharmaceutical company recorded success last performed by Tesla Inc.

We are also available at +357 25 054 734
© 2021 APME FX TRADING EUROPE LTD

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 0% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Read our Risk Disclosures